Clinical trials: Allergies
Asthma
A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device
This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of two different formulations of indacaterol maleate, both administered via the Concept1 device.
- Trial name
- NCT01484197
- Testing
- 75 µg indacaterol maleate (LB), 75 µg indacaterol maleate (PoS), 37.5 µg indacaterol maleate (PoS)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes
Mechanisms of Glucose Lowering Effect of Colesevelam HCl
The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with…
- Trial name
- NCT00596427
- Testing
- Colesevelam HCL
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Carine Beysen
Allergy
Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen rhinoconjunctivitis
- Trial name
- NCT00418379
- Testing
- 300 IR (4M), 300 IR (2M)
- Where
- France
- Volunteers
- 633 people
- Sponsor
- Stallergenes Greer
Dentin Sensitivity
A Pilot Study to Assess Nominal Versus Controlled Stimuli on Dentinal Hypersensitivity
This pilot study will evaluate the use of nominal stimuli to assess dentinal hypersensitivity response relative to a clinically-controlled stimulus.
- Trial name
- NCT02406573
- Testing
- Crest® Sensi-Stop™ Strips
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Atopic Dermatitis, Eczema
Steroid-reducing Effects of Crisaborole
Atopic dermatitis, or eczema, is a chronic skin condition affecting many children. Crisaborole is a non-steroid topical medication which is FDA approved for children aged 2 and older for eczema.
- Trial name
- NCT03832010
- Testing
- Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Hypersensitivity, Immediate Hypersensitivity
Oral Immunotherapy for Childhood Egg Allergy
The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.
- Conditions
- Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
- Trial name
- NCT00461097
- Testing
- Egg oral immunotherapy, Control Group
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
The study will measure the change in lung function in subjects with asthma after inhaling from either of two inhalers: Albuterol Spiromax® or placebo.
- Trial name
- NCT01424813
- Testing
- Albuterol MDPI
- Where
- 38 sites in United States
- Volunteers
- 158 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
- Trial name
- NCT03664960
- Testing
- AK002
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allakos Inc.
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
- Trial name
- NCT01446159
- Testing
- MEDI-573, Aromatase Inhibitor
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
Asthma
Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec
Rationale Asthma is a chronic inflammatory disorder of the airways affecting persons of all ages and is recognized as one of the most common chronic diseases.
- Trial name
- NCT02153346
- Testing
- Valuation of lost productivity questionnaire, Work productivity and activity impairment questionnaire
- Where
- Canada
- Volunteers
- 101 people
- Sponsor
- GlaxoSmithKline
Allergic Conjunctivitis
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
- Trial name
- NCT00534794
- Testing
- Elestat, Pataday
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)
Hypotheses: 1) Airway pH regulation is abnormal in severe asthma; 2) In severe asthma, there is formation of cytotoxic nitrogen oxides and loss of beneficial nitrogen oxides in the airways
- Trial name
- SARP (NCT00590005)
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Emory University
Visceral Hypersensitivity, Irritable Bowel Syndrome
Rifaximin on Visceral Hypersensitivity
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders, with a global prevalence of 11% according to a recent meta-analysis.
- Trial name
- NCT03462966
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Asthma, Exercise-Induced
Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)
To determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as exercise-induced bronchospasm), in…
- Trial name
- NCT00245570
- Testing
- Comparator: Montelukast, Comparator: Salmeterol
- Volunteers
- 47 people
- Sponsor
- Organon and Co
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer
Allergic Bronchopulmonary Aspergillosis
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA).
- Trial name
- NCT04442269
- Testing
- dupilumab
- Where
- 50 sites in United States, Bulgaria and 8 more
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
A study in 2-5 year old children to evaluate the safety and tolerability of montelukast and placebo administered once daily at bed time.
- Trial name
- NCT00968201
- Testing
- montelukast sodium
- Volunteers
- 689 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Asthma
Airway Smooth Muscle and Asthma Severity
Our hypothesis is that the severity of asthma is determined by the way in which airway smooth muscle cells grow and release inflammatory mediators.
- Trial name
- NCT00779870
- Testing
- bronchoscopy
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Imperial College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.